Table 5. Data compliance (% indicates percentage of patients who attended visit).
| EOX (n=17) | OX (n=19) | X (n=19) | Total (n=55) | |
|---|---|---|---|---|
|
QoL questionnaire | ||||
| Baseline CHA | 16 (94%) | 19 (100%) | 19 (100%) | 54 (98%) |
| 6-Week TA | 8 (73%) | 15 (79%) | 12 (67%) | 35 (67%) |
| 12-Week LHA | 8 (73%) | 12 (71%) | 9 (90%) | 29 (76%) |
| 24-Week LHA | 8 (100%) | 8 (73%) | 4 (50%) | 20 (74%) |
Abbreviations: CHA=Comprehensive Health Assessment; EOX=epirubicin, oxaliplatin and capecitabine; LHA=Limited Health Assessment; OX=oxaliplatin and capecitabine; QoL=quality of life; SAR=serious adverse reaction; TA=Toxicity Assessment; X=capecitabine.